主页 > 医学信息 >
【文摘发布】西罗莫司洗脱支架与裸支架治疗急
Author：Maurizio Menichelli, MD*,*, Antonio Parma, MD*, Edoardo Pucci, MD*, Rosario Fiorilli, MD*, Francesco De Felice, MD*, Marco Nazzaro, MD*, Alessia Giulivi, MD*, Domenico Alborino, MD*, Arianna Azzellino, PhD and Roberto Violini, MD*
Objectives: To confirm whether sirolimus-eluting stents (SES) safely reduce the incidence of restenosis in patients with ST-segment elevation acute myocardial infarction compared with bare-metal stents (BMS).
Background: In the setting of primary angioplasty, stent restenosis occurs in up to 27% of patients. The introduction of drug-eluting stents has drastically reduced the incidence of restenosis in clinically stable patients.
Methods: We conducted a randomized trial of 320 patients with acute ST-segment elevation myocardial infarction assigned to receive SES or BMS. The primary end point was binary restenosis at 1-year angiographic follow-up.
Results: At 1 year, the incidence of binary restenosis was lower in the SES group than in the BMS group (9.3% vs. 21.3%, respectively; p = 0.032), as were the rates of target lesion revascularization (4.3% vs. 11.2%; p = 0.02), target vessel revascularization (5% vs. 13.1; p = 0.015), major adverse cardiac events (6.8% vs. 16.8%; p = 0.005), and target vessel failure (8.7% vs. 18.7%; p = 0.007). The incidence of angiographically documented stent thrombosis was 1.2% (n = 2) in the SES group and 0.6% (n = 1) in the BMS group.
Conclusions: In patients with acute myocardial infarction, SES are superior to BMS, reducing the incidence of binary restenosis by 56%, target lesion revascularization by 61%, target vessel revascularization by 62%, adverse cardiac events by 59%, and target vessel failure by 53% at 1 year.
http://content.onlinejacc.org/cgi/content/abstract/49/19/1924?etoc 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title：Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI)
题目：西罗莫司洗脱支架与金属裸支架治疗急性心梗的随机对照研究
Author：Maurizio Menichelli, MD*,*, Antonio Parma, MD*, Edoardo Pucci, MD*, Rosario Fiorilli, MD*, Francesco De Felice, MD*, Marco Nazzaro, MD*, Alessia Giulivi, MD*, Domenico Alborino, MD*, Arianna Azzellino, PhD and Roberto Violini, MD*
作者：Maurizio Menichelli, MD*,*, Antonio Parma, MD*, Edoardo Pucci, MD*, Rosario Fiorilli, MD*, Francesco De Felice, MD*, Marco Nazzaro, MD*, Alessia Giulivi, MD*, Domenico Alborino, MD*, Arianna Azzellino, PhD and Roberto Violini, MD*
Objectives: To confirm whether sirolimus-eluting stents (SES) safely reduce the incidence of restenosis in patients with ST-segment elevation acute myocardial infarction compared with bare-metal stents (BMS).
目的：为了证实西罗莫司洗脱支架(SES)与金属裸(BMS)支架相比，是否可以有效降低伴有ST段抬高的心梗病人再狭窄的发生率。
Background: In the setting of primary angioplasty, stent restenosis occurs in up to 27% of patients. The introduction of drug-eluting stents has drastically reduced the incidence of restenosis in clinically stable patients.
背景：在进行初次血管成型术的病人中，有大约27％会发生支架内再狭窄。在处于临床稳定期的病人中，药物洗脱支架的应用可明显降低再狭窄的发生率。
Methods: We conducted a randomized trial of 320 patients with acute ST-segment elevation myocardial infarction assigned to receive SES or BMS. The primary end point was binary restenosis at 1-year angiographic follow-up.
方法：我们对320名因患有急性ST段抬高型心肌梗塞而接受SES或BMS治疗的病人进行了随机对照研究。经血管造影随访，发生再狭窄的主要终点时间为1年（此句不是很确定）。
Results: At 1 year, the incidence of binary restenosis was lower in the SES group than in the BMS group (9.3% vs. 21.3%, respectively; p = 0.032), as were the rates of target lesion revascularization (4.3% vs. 11.2%; p = 0.02), target vessel revascularization (5% vs. 13.1; p = 0.015), major adverse cardiac events (6.8% vs. 16.8%; p = 0.005), and target vessel failure (8.7% vs. 18.7%; p = 0.007). The incidence of angiographically documented stent thrombosis was 1.2% (n = 2) in the SES group and 0.6% (n = 1) in the BMS group.
结果：1年后，SES组的再狭窄发生率低于BMS组（分别为9.3％和21.3％；p=0.032），靶病变血运重建率（4.3％vs11.2％；p=0.02）、靶血管血运重建率（5％vs13.1％；p=0.015）、心脏的主要副作用（6.8％vs16.8％；p=0.005）和靶血管失效率（8.7％vs18.7％；p=0.007）也是如此。经血管造影确诊的支架内血栓形成率，在SES组为1.2％(n = 2)，在BMS组为0.6％(n = 1)。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-11 17:12
医学,生命科学网